Literature DB >> 11588068

FDA warns Merck over its promotion of rofecoxib.

D Josefson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11588068      PMCID： PMC1121328     

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

Review 1.  Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis.

Authors:  Michael T Nurmohamed; Vokko P van Halm; Ben A C Dijkmans
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Does paracetamol potentiate the effects of oral anticoagulants?: a literature review.

Authors:  Isabelle Mahé; Charles Caulin; Jean-François Bergmann
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 3.  Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors.

Authors:  C J Hawkey; M J S Langman
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

4.  Is new drug prescribing in primary care specialist induced?

Authors:  Stefan R Florentinus; Eibert R Heerdink; Liset van Dijk; A M G Fabiënne Griens; Peter P Groenewegen; Hubert G M Leufkens
Journal:  BMC Health Serv Res       Date:  2009-01-11       Impact factor: 2.655
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.